Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression

Cancer Biology and Therapy

Volumn 15, Issue 8, 2014, Pages 1077-1086

  Doi, Kenichiro ^a   Liu, Qiang ^a   Gowda, Krishne ^a   Barth, Brian M ^b   Claxton, David ^b   Amin, Shantu ^a   Loughran Jr, Thomas P ^b,c   Wang, Hong Gang ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

ABT 737; Acute myeloid leukemia; Bcl 2; Leukemia; Maritoclax; Mcl 1

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTILEUKEMIC AGENT; BETA ACTIN; BIM PROTEIN; CASPASE 3; DAUNORUBICIN; MARITOCLAX; MESSENGER RNA; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN INHIBITOR; PROTEIN MCL 1; UNCLASSIFIED DRUG; ABT-737; ANTINEOPLASTIC AGENT; BIPHENYL DERIVATIVE; MARINOPYRROLE A; MCL1 PROTEIN, HUMAN; NITROPHENOL; PIPERAZINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER RESISTANCE; DOWN REGULATION; FEMALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; COCULTURE; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; GENETICS; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA, MYELOID, ACUTE; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIPHENYL COMPOUNDS; BONE MARROW CELLS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DAUNORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HEMATOPOIETIC STEM CELLS; HETEROGRAFTS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICE, INBRED C57BL; MICE, NUDE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NITROPHENOLS; PIPERAZINES; PYRROLES; RNA INTERFERENCE; STROMAL CELLS; SULFONAMIDES;

EID: 84905439095     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.29186     Document Type: Article

References (35)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30; PMID:23335087; http://dx.doi.org/10.3322/caac.21166
2. O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Goorha S, et al. Acute myeloid leukemia. J Natl Compr Canc Netw 2012; 10:984-1021; PMID:22878824
3. Kaufmann SH, Karp JE, Svingen PA, Krajewski S, Burke PJ, Gore SD, Reed JC. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 1998; 91:991-1000; PMID:9446661
4. Liu Q, Wang H-G. Anti-cancer drug discovery and development: Bcl-2 family small molecule inhibitors. Commun Integr Biol 2012; 5:557-65; PMID:23336025; http://dx.doi.org/10.4161/cib.21554
5. Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD, Izon DJ, Zuber J, Rappaport AR, Herold MJ, et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev 2012; 26:120-5; PMID:22279045; http://dx.doi.org/10.1101/gad.182980.111
6. Yoshimoto G, Miyamoto T, Jabbarzadeh-Tabrizi S, Iino T, Rocnik JL, Kikushige Y, Mori Y, Shima T, Iwasaki H, Takenaka K, et al. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood 2009; 114:5034-43; PMID:19808698; http://dx.doi.org/10.1182/blood-2008-12-196055
7. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435:677-81; PMID:15902208; http://dx.doi.org/10.1038/nature03579
8. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011; 29:909-16; PMID:21282543; http://dx.doi.org/10.1200/JCO.2010.31.6208
9. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19:202-8; PMID:23291630; http://dx.doi.org/10.1038/nm.3048
10. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi Y-X, Sneed T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10:375-88; PMID:17097560; http://dx.doi.org/10.1016/j.ccr.2006.10.006
11. Hermanson DL, Das SG, Li Y, Xing C. Overexpression of Mcl-1 confers multidrug resistance, whereas topoisomerase IIβ downregulation introduces mitoxantrone-specific drug resistance in acute myeloid leukemia. Mol Pharmacol 2013; 84:236-43; PMID:23696245; http://dx.doi.org/10.1124/mol.113.086140
12. Balakrishnan K, Burger JA, Wierda WG, Gandhi V. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 2009; 113:149-53; PMID:18836097; http://dx.doi.org/10.1182/ blood-2008-02-138560
13. Aliabadi HM, Mahdipoor P, Uludaǧ H. Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drugresistant breast cancer cells. Cancer Gene Ther 2013; 20:169-77; PMID:23449477; http://dx.doi.org/10.1038/cgt.2013.8
14. Rinkenberger JL, Horning S, Klocke B, Roth K, Korsmeyer SJ. Mcl-1 deficiency results in periimplantation embryonic lethality. Genes Dev 2000; 14:23-7; PMID:10640272
15. Opferman JT, Iwasaki H, Ong CC, Suh H, Mizuno S, Akashi K, Korsmeyer SJ. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 2005; 307:1101-4; PMID:15718471; http://dx.doi.org/10.1126/ science.1106114
16. Wang X, Bathina M, Lynch J, Koss B, Calabrese C, Frase S, Schuetz JD, Rehg JE, Opferman JT. Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev 2013; 27:1351-64; PMID:23788622; http://dx.doi.org/10.1101/gad.215855.113
17. Thomas RL, Roberts DJ, Kubli DA, Lee Y, Quinsay MN, Owens JB, Fischer KM, Sussman MA, Miyamoto S, Gustafsson AB. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev 2013; 27:1365-77; PMID:23788623; http://dx.doi.org/10.1101/gad.215871.113
18. Rahmani M, Davis EM, Bauer C, Dent P, Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem 2005; 280:35217-27; PMID:16109713; http://dx.doi.org/10.1074/jbc.M506551200
19. Kasper S, Breitenbuecher F, Heidel F, Hoffarth S, Markova B, Schuler M, Fischer T. Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies. Blood Cancer J 2012; 2:e60; PMID:22829255; http://dx.doi.org/10.1038/ bcj.2012.5
20. Ma Y, Cress WD, Haura EB. Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1. Mol Cancer Ther 2003; 2:73-81; PMID:12533675
21. Doi K, Li R, Sung S-S, Wu H, Liu Y, Manieri W, Krishnegowda G, Awwad A, Dewey A, Liu X, et al. Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. J Biol Chem 2012; 287:10224-35; PMID:22311987; http://dx.doi.org/10.1074/jbc.M111.334532
22. Pandey MK, Gowda K, Doi K, Sharma AK, Wang H-G, Amin S. Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells. PLoS One 2013; 8:e78570; PMID:24223823; http://dx.doi.org/10.1371/journal.pone.0078570
23. Hughes CC, Prieto-Davo A, Jensen PR, Fenical W. The marinopyrroles, antibiotics of an unprecedented structure class from a marine Streptomyces sp. Org Lett 2008; 10:629-31; PMID:18205372; http://dx.doi.org/10.1021/ol702952n
24. Chen S, Dai Y, Harada H, Dent P, Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007; 67:782-91; PMID:17234790; http://dx.doi.org/10. 1158/0008-5472.CAN-06-3964
25. Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells that upregulate MCL-1 and BFL-1. Blood 2010; 115:3304-13; PMID:20197552; http://dx.doi.org/10.1182/blood-2009-07-233304
26. Garrido SM, Appelbaum FR, Willman CL, Banker DE. Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol 2001; 29:448-57; PMID:11301185; http://dx.doi.org/10.1016/S0301-472X(01)00612-9
27. Gores GJ, Kaufmann SH. Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors. Genes Dev 2012; 26:305-11; PMID:22345513; http://dx.doi.org/10.1101/gad.186189.111
28. Eichhorn JM, Alford SE, Hughes CC, Fenical W, Chambers TC. Purported Mcl-1 inhibitor marinopyrrole A fails to show selective cytotoxicity for Mcl-1-dependent cell lines. Cell Death Dis 2013; 4:e880; PMID:24157874; http://dx.doi.org/10.1038/cddis.2013.411
29. Ding Q, He X, Hsu J-M, Xia W, Chen C-T, Li L-Y, Lee D-F, Liu J-C, Zhong Q, Wang X, et al. Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol 2007; 27:4006-17; PMID:17387146; http://dx.doi.org/10.1128/MCB.00620-06
30. Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS, Zhai B, Wan L, Gutierrez A, Lau AW, et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 2011; 471:104-9; PMID:21368833; http://dx.doi.org/10.1038/nature09732
31. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, Nakamura R, Tanaka T, Tomiyama H, Saito N, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007; 25:1315-21; PMID:17952057; http://dx.doi.org/10.1038/nbt1350
32. Krajewski S, Bodrug S, Gascoyne R, Berean K, Krajewska M, Reed JC. Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes. Am J Pathol 1994; 145:515-25; PMID:8080035
33. Cheng C, Pan L, Chen Y, Song H, Qin Y, Li R. Total synthesis of (+/-)-marinopyrrole A and its library as potential antibiotic and anticancer agents. J Comb Chem 2010; 12:541-7; PMID:20429575; http://dx.doi.org/10.1021/ cc100052j
34. Woods NT, Yamaguchi H, Lee FY, Bhalla KN, Wang H-G. Anoikis, initiated by Mcl-1 degradation and Bim induction, is deregulated during oncogenesis. Cancer Res 2007; 67:10744-52; PMID:18006817; http://dx.doi.org/10.1158/0008-5472.CAN- 07-3148
35. Bliss CI. The calculation of microbial assays. Bacteriol Rev 1956; 20:243-58; PMID:13403845